DexCom, Inc. (DXCM), with a market cap of $33.9 billion, is a leading medical device company specializing in continuous ...

Medical device company DexCom (NASDAQ:DXCM) in Q1 CY2025, with sales up 12.5% year on year to $1.04 billion. The company ...

25 analysts are following DexCom and have set target prices ranging from $82.0 to $110.0 per share. On average, they have ...

The medical instruments industry is currently undergoing a transformative phase, thanks to the rapid adoption of generative ...

DexCom Inc. closed 34.58% short of its 52-week high of $132.26, which the company reached on May 17th.

Shares of DexCom Inc. DXCM shed 1.11% to $84.11 Tuesday, on what proved to be an all-around mixed trading session for the ...

Dexcom (Nasdaq:DXCM) announced today that it promoted Jake Leach to the role of president, in addition to his post as COO.

DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose biosensing, today announced the promotion of ...

DexCom's Q1 2025 earnings show strong growth potential, but cost pressures are impacting margins. Check out why I am lowering my rating on DXCM from buy to hold.

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products ...

Dexcom (NASDAQ:DXCM) announced today that it expanded its partnership with Oura, officially launching an integration with ...